NEWSROOM
News Releases
The latest news about Samsung Bioepis
- Samsung Bioepis Releases Second Quarter 2024 US Biosimilar Market Report 08/04/2024
- Samsung Bioepis Initiates Phase 3 Clinical Trial for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab) 05/04/2024
- Samsung Invests in BrickBio to Develop Advanced Molecules and Therapies Using Protein Engineering Technology for Antibody-Drug Conjugates (ADC) 18/03/2024
- Samsung Bioepis Presents Two Abstracts for Its Immunology Portfolio at the 2024 American Academy of Dermatology (AAD) Annual Meeting 09/03/2024
- Samsung Bioepis Presents Two Abstracts for SB17, a Proposed Biosimilar to Stelara (Ustekinumab), at the 19th Annual Congress of European Crohn’s and Coliti... 22/02/2024
- Samsung Bioepis Initiates Phase 1 Clinical Trial for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab) 21/02/2024
